Regeneron/Sanofi cholesterol drug gets FDA priority review
January 26, 2015 at 01:00 AM EST
Jan 26 (Reuters) - Regeneron Pharmaceuticals on Monday said U.S. health regulators accepted its application to review a potent cholesterol drug on a priority basis, potentially giving it the upper hand in a fierce race with Amgen to bring a new medicine from the promising class to market.